Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
99 participants
INTERVENTIONAL
2024-02-06
2024-07-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Does the medical device induce skin irritation in the ear canal?
* Does the medical device reduce obstruction of ear canal induced by excessive cerumen?
Participants will use the device in each ear, once a day, every 3 days at home. Researchers will compare the medical device group to a control group who will not use the medical device.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Irritancy/Allergic Sensitivity to Natural Personal-care Products by Patch Tests
NCT01816542
Study About Effectiveness of Silver-Containing Textiles for Treatment of Acute Neurodermatitis
NCT00196430
Assessment of Skin Barrier Disruption Due to Daily Use of Cleaning Products and Hand Disinfectants
NCT06269315
Xerotic Dermatitis in Aged People
NCT01806935
A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants
NCT06934980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This clinical investigation is designed to improve the quality and quantity of data available on both the safety and the efficacy of Ocean Bio-Actif, in order to confirm the safety and the efficacy of the product in a post-market environment.
The objective of the current clinical investigation is to confirm the efficacy and safety of topical application to the ear canal of Ocean Bio-Actif.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Auricular spray
Subjects using the medical device under investigation: 2 sprays in each ear, every 3 days at home.
Ear Hygiene
2 sprays in each ear, every 3 days at home
Control
Subjects not using any spray (can use ear drops in case of discomfort or pain)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ear Hygiene
2 sprays in each ear, every 3 days at home
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age:
30 to 40% having age between 3 to 12 yo, 30 to 40% between 13 to 65 yo, 30 to 40% more than 65 yo.
* Subjects able to use the tested product.
* Subjects having history of cerumen occlusion more than once a year with or without symptoms (reduction of hearing function, obstruction feeling of the ear canal,..).
* Subjects having ear help system or regular users of systems such as anti-noise plugs or headsets (only for the 13yo subjects and more).
* Subjects having a clinical score of ear canal obstruction of 2 or 3 at D0.
Exclusion Criteria
* Subjects who had severe troubles of the internal ear (severe dizziness, desorientation, nausea).
* Subjects using regularly a ear spray for washing his/her ears.
* Subjects having a score of ear canal obstruction at 4 at D0.
* Pregnant or nursing woman or planning a pregnancy during the study;
* Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship;
* Subject in a social or sanitary establishment;
* Subject suspected to be non-compliant according to the investigator's judgment;
* Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk;
* Subject suffering from a severe or progressive disease.
3 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
YSLab
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iwona MAZUREWICZ
Role: PRINCIPAL_INVESTIGATOR
Eurofins Dermscan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eurofins Dermscan Poland
Gdansk, Ul. Matuszewskiego 12, Poland
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23E1670
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.